<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01642134</url>
  </required_header>
  <id_info>
    <org_study_id>MEIX-VALV-001</org_study_id>
    <secondary_id>2011-005784-24</secondary_id>
    <nct_id>NCT01642134</nct_id>
  </id_info>
  <brief_title>Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI</brief_title>
  <acronym>AUREA</acronym>
  <official_title>PHASE IV Study of Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After Percutaneous Aortic Valve Implantation. Multicenter Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andres Iñiguez Romo, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Meixoeiro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the incidence of major vascular events (ischemic or
      haemorrhagics) at the third month after initiation of the antithrombotic treatment (oral
      anticoagulation or dual antiplatelet therapy) in both arms followed TAVI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter aortic valve implantation (TAVI) procedure using any of their vascular access
      is an option with proven benefit definitively for treatment of severe symptomatic aortic
      stenosis in patients considered unsuitable for conventional open heart surgery.

      By avoiding the hemodynamic effects, cardiovascular and cerebral microembolic load of
      cardiopulmonary bypass circulation, it is assumed that the TAVI procedure is beneficial
      despite the risk of neurological complications. Currently antithrombotic therapy after the
      procedure is not standardized. International treatment guidelines recommends that
      post-operative patients with a conventional surgical aortic bioprosthesis maintain oral
      anticoagulation for 3 months after the procedure, unless otherwise noted for its
      continuation. Whereas some studies have postulated that in patients with aortic
      bioprostheses, dual antiplatelet therapy is as effective to prevent major cardiac and
      cerebrovascular events as oral anticoagulation, with a lower incidence of bleeding
      complications at 3 months of treatment, the investigators formulated the following
      hypothesis:

      • There is a lower incidence of major cardiac and cerebrovascular events in patients with
      dual antiplatelet therapy compared to patients with oral anticoagulation for 3 months after
      implantation of an aortic bioprosthesis TAVI procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effectiveness of dual antiplatelet therapy versus oral anticoagulation for prevention of cerebral thromboembolism by the detection of new areas of cerebral infarction by Magnetic Resonance Imaging (MRI) 3 months after TAVI.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of new areas of cerebral infarction by MRI between the different routes of vascular access and the various valve devices.</measure>
    <time_frame>1 hour before TAVI, 1 hour and 24 hours after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify the development of cognitive impairment after TAVI</measure>
    <time_frame>Pre-TAVI, and at 1º 3º and 6º month after TAVI</time_frame>
    <description>By the application of: 1)Mini-Mental State Examination (MMSE); 2)SF 36 (spanish version); 3)The NIHSS (National Institute of Health Stroke Scale). The evaluation of the neurological tests will be performed by a certificated neurologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Quality of life after TAVI.</measure>
    <time_frame>Pre-TAVI, and at 1º; 3º and 6º month after TAVI.</time_frame>
    <description>By the application of Euroquol EQ5.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Duoplavin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Both active substances in DuoPlavin: clopidogrel and acetylsalicylic acid, are inhibitors of platelet aggregation. Clopidogrel stops the platelets aggregating by blocking ADP. Acetylsalicylic acid the platelets aggregating by blocking the prostaglandin cyclo oxygenase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acenocumarol</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin+clopidogrel (Duoplavin)</intervention_name>
    <description>100 mg aspirin ;75 mg clopidogrel 3º months</description>
    <arm_group_label>Duoplavin</arm_group_label>
    <arm_group_label>acenocumarol</arm_group_label>
    <other_name>DUOPLAVIN (aspirin 100 mg + clopidogrel 75 mg).</other_name>
    <other_name>SINTROM (ACENOCUMAROL).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients (more than 18 years) with ability to understand and accept the
             participation in the clinical trial.

          2. Patients with symptomatic degenerative severe aortic stenosis rejected for
             conventional surgical aortic valve replacement due to unacceptably high risk and
             accepted for TAVI procedure

          3. Signed informed consent.

          4. Patients who are not participating in any other clinical trial or research study.

        Exclusion Criteria:

          1. Patients under oral anticoagulation treatment

          2. Patients who can not undergo MRI study

          3. Recent stroke &lt; 14 days prior, revascularized coronary artery disease or life
             expectancy &lt; 12 months

          4. Patients with proven allergy to aspirin, clopidogrel or acenocoumarol

          5. Patients that after TAVI procedure can not undergo a regimen of dual antiplatelet
             therapy or oral anticoagulation for 3 months due to any new post-TAVI medical
             indication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Iniguez Romo, MD;PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Alvaro Cunqueiro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor A. Jimenez Diaz, MD;Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital clinico universitario Vigo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariano Larman Tellechea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlínica de Guipuzcoa SA San Sebastián</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Juan Salvadores, Pharma,MPH</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Álvaro Cunqueiro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose M. Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de la Victoria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pablo Juan Salvadores, Pharma, MPH</last_name>
    <phone>0034986825564</phone>
    <phone_ext>514564</phone_ext>
    <email>pablo.juan.salvadores@sergas.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victor A. Jimenez Díaz, MD, MPH</last_name>
    <phone>0034986825564</phone>
    <phone_ext>514564</phone_ext>
    <email>victor.alfonso.jimenez.diaz@sergas.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Policlínica de Guipuzcoa.SA</name>
      <address>
        <city>San Sebastián</city>
        <state>Guipúzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mariano Larman Tellechea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Victor A. Jimenez Diaz, MD,MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose A. Baz Alonso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Juan Salvadores, PHARMA, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andres Iñiguez Romo, MD, pHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital clinico Universitario Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>36201</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Ramon Cequier Fillat, MD</last_name>
    </contact>
    <investigator>
      <last_name>Angel Ramon Cequier Fillat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Malaga</name>
      <address>
        <city>Malaga</city>
        <zip>36201</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose maria hernandez, md</last_name>
    </contact>
    <investigator>
      <last_name>Jose maria Hernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cardiologia-vigo.com/</url>
  </link>
  <reference>
    <citation>Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011 Jun 9;364(23):2187-98. doi: 10.1056/NEJMoa1103510. Epub 2011 Jun 5.</citation>
    <PMID>21639811</PMID>
  </reference>
  <reference>
    <citation>Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. doi: 10.1056/NEJMoa1008232. Epub 2010 Sep 22.</citation>
    <PMID>20961243</PMID>
  </reference>
  <reference>
    <citation>Kahlert P, Knipp SC, Schlamann M, Thielmann M, Al-Rashid F, Weber M, Johansson U, Wendt D, Jakob HG, Forsting M, Sack S, Erbel R, Eggebrecht H. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation. 2010 Feb 23;121(7):870-8. doi: 10.1161/CIRCULATIONAHA.109.855866.</citation>
    <PMID>20177005</PMID>
  </reference>
  <reference>
    <citation>Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke. 2000 Nov;31(11):2670-7.</citation>
    <PMID>11062293</PMID>
  </reference>
  <reference>
    <citation>Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA; EACTS Audit and Guidelines Committee. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg. 2008 Jul;34(1):73-92. doi: 10.1016/j.ejcts.2008.02.024. Epub 2008 Mar 28. Review. Erratum in: Eur J Cardiothorac Surg. 2008 Oct;34(4):934.</citation>
    <PMID>18375137</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Meixoeiro</investigator_affiliation>
    <investigator_full_name>Andres Iñiguez Romo, MD, PhD</investigator_full_name>
    <investigator_title>MD; PHD</investigator_title>
  </responsible_party>
  <keyword>Antiplatelet</keyword>
  <keyword>Anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Intracranial Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Acenocoumarol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

